Desperate Housewife Dana flacks Caltrate

Share this article:

Desperate Housewives star Dana Delany will serve as the face of Pfizer's “Women Move the World” campaign for the OTC calcium and vitamin D supplement Caltrate.

The 55-year-old actress, currently starring in the TV crime drama Body of Proof, will issue a “national call-to-action inviting women everywhere to share their individual stories and everyday accomplishments” through the brand's Facebook page and at Susan G. Komen Race for the Cure events, for which the brand will be a national sponsor. 

Some women sharing girl-power-themed tales on Facebook, ranging from everyday accomplishments to long-term personal successes, will be tapped to appear in ads.

“I love that ‘Women Move the World' recognizes the accomplishments women achieve every single day,” said Delany in a statement. “I want to thank the women in my life who have inspired me to join Caltrate in this celebration. Together, we encourage all women to keep their bodies strong, so they can keep moving themselves and the world forward.”

Marina Maher Communications is handling the PR campaign.

Pfizer will donate $100,000 to Susan G. Komen Race for the Cure through March 2012 in Caltrate's name. The company will post Caltrate booths at Komen races, where attendees can get samples or submit their stories to the campaign.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?